Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities

Mehrdad Hefazi, Mustaqeem Siddiqui, Mrinal M Patnaik, Alexandra Wolanskyj, Hassan Alkhateeb, Darci Zblewski, Michelle Elliott, William Hogan, Mark R Litzow, Aref Al-Kali

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

The prognostic impact of combined NPM1+/FLT3- genotype is not well defined in elderly patients with acute myeloid leukemia (AML), and in the setting of different treatments, such as cytotoxic chemotherapy (Chemo), hematopoietic cell transplantation (HCT), or hypomethylating agents (HMA). Eighty-two elderly (age > 60 years) and 78 younger adults (age 18-60 years) with newly diagnosed intermediate-risk cytogenetic AML were classified according to the presence or absence of NPM1+/FLT3- genotype, and treatments (Chemo vs. HCT. vs. HMA). The estimated 3-year overall survivals (OS) in elderly (N=17) and younger adults (N=13) with NPM1+/FLT3- treated with Chemo were 59% and 64%, respectively (P=0.71). In the absence of NPM1+/FLT3-, younger adults had a superior OS when treated with HCT than with Chemo (P<0.0001), but elderly showed no survival advantage with HCT after adjustment for baseline covariates. Elderly patients lacking NPM1+/FLT3- had a comparable OS when treated with Chemo vs. HMA (P=0.79). Combined NPM1+/FLT3- is associated with a favorable prognosis irrespective of age in AML patients treated with Chemo. In the absence of NPM1+/FLT3- genotype, younger adults undergoing HCT have an improved survival, while elderly have comparable OS when treated with Chemo vs. HMA.

Original languageEnglish (US)
Pages (from-to)1207-1213
Number of pages7
JournalLeukemia Research
Volume39
Issue number11
DOIs
StatePublished - Jul 31 2015

Keywords

  • Acute myeloid leukemia
  • Elderly
  • FLT3
  • NPM1
  • Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities'. Together they form a unique fingerprint.

  • Cite this